Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 1
1998 2
2000 4
2002 1
2003 3
2004 2
2005 2
2006 4
2007 4
2008 6
2009 5
2010 24
2011 27
2012 35
2013 28
2014 31
2015 29
2016 39
2017 34
2018 43
2019 38
2020 15
Text availability
Article attribute
Article type
Publication date

Search Results

327 results
Results by year
Filters applied: . Clear all
Page 1
Ulipristal acetate versus leuprolide acetate for uterine fibroids.
Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F, Nouri K, Selvaggi L, Sodowski K, Bestel E, Terrill P, Osterloh I, Loumaye E; PEARL II Study Group. Donnez J, et al. N Engl J Med. 2012 Feb 2;366(5):421-32. doi: 10.1056/NEJMoa1103180. N Engl J Med. 2012. PMID: 22296076 Free article. Clinical Trial.
Median times to amenorrhea were 7 days for patients receiving 5 mg of ulipristal acetate, 5 days for those receiving 10 mg of ulipristal acetate, and 21 days for those receiving leuprolide acetate. Moderate-to-severe hot flashes were reported for 11% of patients rec …
Median times to amenorrhea were 7 days for patients receiving 5 mg of ulipristal acetate, 5 days for those receiving 10 mg of ulip …
Ulipristal acetate versus placebo for fibroid treatment before surgery.
Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, Ugocsai G, Mara M, Jilla MP, Bestel E, Terrill P, Osterloh I, Loumaye E; PEARL I Study Group. Donnez J, et al. N Engl J Med. 2012 Feb 2;366(5):409-20. doi: 10.1056/NEJMoa1103182. N Engl J Med. 2012. PMID: 22296075 Free article. Clinical Trial.
RESULTS: At 13 weeks, uterine bleeding was controlled in 91% of the women receiving 5 mg of ulipristal acetate, 92% of those receiving 10 mg of ulipristal acetate, and 19% of those receiving placebo (P<0.001 for the comparison of each dose of ulipristal ac …
RESULTS: At 13 weeks, uterine bleeding was controlled in 91% of the women receiving 5 mg of ulipristal acetate, 92% of those receivin …
Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial.
Liu JH, Soper D, Lukes A, Gee P, Kimble T, Kroll R, Mallick M, Chan A, Gillard P, Harrington A, Sniukiene V, Shulman LP. Liu JH, et al. Obstet Gynecol. 2018 Nov;132(5):1241-1251. doi: 10.1097/AOG.0000000000002942. Obstet Gynecol. 2018. PMID: 30303900 Clinical Trial.
METHODS: This phase 3, double-blind, double-dummy, placebo-controlled trial randomized premenopausal women (18-50 years) with uterine leiomyomas and abnormal uterine bleeding to once-daily 5 mg ulipristal, 10 mg ulipristal, or placebo in two 12-week treatment course …
METHODS: This phase 3, double-blind, double-dummy, placebo-controlled trial randomized premenopausal women (18-50 years) with uterine leiomy …
Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis.
Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, Sogor L, Blithe DL, Scherrer B, Mathe H, Jaspart A, Ulmann A, Gainer E. Glasier AF, et al. Lancet. 2010 Feb 13;375(9714):555-62. doi: 10.1016/S0140-6736(10)60101-8. Epub 2010 Jan 29. Lancet. 2010. PMID: 20116841 Clinical Trial.
FINDINGS: In the efficacy-evaluable population, 1696 women received emergency contraception within 72 h of sexual intercourse (ulipristal acetate, n=844; levonorgestrel, n=852). There were 15 pregnancies in the ulipristal acetate group (1.8%, 95% CI 1.0-3.0) and 22 …
FINDINGS: In the efficacy-evaluable population, 1696 women received emergency contraception within 72 h of sexual intercourse (ulipristal …
Uterine fibroid management: from the present to the future.
Donnez J, Dolmans MM. Donnez J, et al. Hum Reprod Update. 2016 Nov;22(6):665-686. doi: 10.1093/humupd/dmw023. Epub 2016 Jul 27. Hum Reprod Update. 2016. PMID: 27466209 Free PMC article. Review.
The economic impact of uterine fibroid management is significant and it is imperative that new treatments be developed to provide alternatives to surgical intervention.There is growing evidence of the crucial role of progesterone pathways in the pathophysiology of uterine fibroid …
The economic impact of uterine fibroid management is significant and it is imperative that new treatments be developed to provide alternativ …
Endometrial changes during ulipristal acetate use: A systematic review.
De Milliano I, Van Hattum D, Ket JCF, Huirne JAF, Hehenkamp WJK. De Milliano I, et al. Eur J Obstet Gynecol Reprod Biol. 2017 Jul;214:56-64. doi: 10.1016/j.ejogrb.2017.04.042. Epub 2017 Apr 28. Eur J Obstet Gynecol Reprod Biol. 2017. PMID: 28482329 Review.
Several studies have been performed to evaluate this possible increased risk for endometrial malignancies when using ulipristal acetate. The specific spectrum of morphological changes due to ulipristal acetate, named progesterone receptor modulator associated endome …
Several studies have been performed to evaluate this possible increased risk for endometrial malignancies when using ulipristal aceta …
Choice of contraceptives.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2018 Oct 8;60(1557):161-168. Med Lett Drugs Ther. 2018. PMID: 30335731 No abstract available.
Ulipristal Acetate for Unscheduled Bleeding in Etonogestrel Implant Users: A Randomized Controlled Trial.
Zigler RE, Madden T, Ashby C, Wan L, McNicholas C. Zigler RE, et al. Obstet Gynecol. 2018 Oct;132(4):888-894. doi: 10.1097/AOG.0000000000002810. Obstet Gynecol. 2018. PMID: 30130351 Free PMC article. Clinical Trial.
Women randomized to ulipristal acetate reported 5 fewer days of bleeding over a 30-day reference period after treatment (P=.002). ...Serum progesterone levels were nonovulatory in a subset of each group (placebo group range: less than 0.2-1.3 ng/mL; ulipristal aceta …
Women randomized to ulipristal acetate reported 5 fewer days of bleeding over a 30-day reference period after treatment (P=.002). ... …
Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids.
Garnock-Jones KP, Duggan ST. Garnock-Jones KP, et al. Drugs. 2017 Oct;77(15):1665-1675. doi: 10.1007/s40265-017-0812-3. Drugs. 2017. PMID: 28900897 Review.
Oral ulipristal acetate (Esmya(); Fibristal()), a synthetic selective progesterone receptor modulator, is the first selective progesterone modulator to be approved for the treatment of uterine fibroids. ...This narrative review summarizes pharmacological, efficacy and tole …
Oral ulipristal acetate (Esmya(); Fibristal()), a synthetic selective progesterone receptor modulator, is the first selective progest …
Emergency Contraception.
Batur P, Kransdorf LN, Casey PM. Batur P, et al. Mayo Clin Proc. 2016 Jun;91(6):802-7. doi: 10.1016/j.mayocp.2016.02.018. Mayo Clin Proc. 2016. PMID: 27261868 Review.
There are 4 approved EC options in the United States. Although ulipristal acetate requires a provider's prescription, oral levonorgestrel (LNG) is available over the counter for women of all ages. ...Women who weigh more than 75 kg or have a body mass index greater than 25 …
There are 4 approved EC options in the United States. Although ulipristal acetate requires a provider's prescription, oral levonorges …
327 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback